Akshatha R Profile picture
MD(JIPMER),DNB,MNAMS,DM ID(AIIMS J), DTMH(UK) RSTMH Student Ambassador ESPID Country representative TID🇨🇭, Phage therapy 🇧🇪 Founder-Learn with Dr Akshatha

Jun 8, 2023, 6 tweets

#IDSA AMR Updates 2023
#IDtwitter
#Medtwitter
Updates in ESBL E
To avoid piptaz in non UTI
To avoid Cefepime
No role of Cephamycins
No role of Ceftalazone - Tazobactam
@CidsIndia
@idcon2022 @id_cure
@IDstewardship

Updates in AmpC
Explained well about How to choose Antibiotics in AmpC -

Updates in CRE -
Explicitly mentions TOC for NDM, OXA, KPC & while awaiting reports.
No role of Tetracycline derivatives in UTI/ BSI

Updates in Pseudo
TOC for MDR Pseudo
TOC for MBL - No added benefit of Ceftazidime -avibactam+Aztreonam vs Aztreonam alone
Combination therapy in DTR Pseudo-Don't use Polymxin+Aminoglycosides -use Newer BL-BLI+Tobramycin if tobra is S, if R use Newer BL-BLI+ Polymyxin

Updates in CRAB
CRAB therapy -Sulbactam + Mino>Tige , or Sulbactam + Polymyxin B, Mero + Poly B not to be used
If using Ampicillin - Sulbactam - panel suggest *against* the use of Meropenem in the combination

Stenotrophomonas updates
Combination only - no role of single agent
Ceftazidime -avibactam + Aztreonam if clinical instability, intolerance

Share this Scrolly Tale with your friends.

A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.

Keep scrolling